Partial fetal alcohol syndrome

Summary

Partial fetal alcohol syndrome (MONDO:0000393) is a disease and 2 clinical trials. Top therapeutic interventions include choline and choline bitartrate. A subtype of fetal alcohol spectrum disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	partial fetal alcohol syndrome
Mondo ID	MONDO:0000393
DOID	DOID:0050666
UMLS	C3661483
MedGen	775682
Is cancer (heuristic)	no

Disease family

This is a subtype of fetal alcohol spectrum disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › developmental disorder of mental health › specific developmental disorder › fetal alcohol spectrum disorder › partial fetal alcohol syndrome

Related subtypes (3): alcohol-related birth defect, fetal alcohol syndrome, neurobehavioral disorder with prenatal alcohol exposure

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01149538	PHASE1/PHASE2	COMPLETED	Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure
NCT01911299	PHASE2	COMPLETED	Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CHOLINE	4	1
CHOLINE BITARTRATE	3	1